Please ensure Javascript is enabled for purposes of website accessibility

Why Emergent BioSolutions Stock Is Falling Again Today

By Keith Speights - Apr 22, 2021 at 11:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst lowered his price target on the stock.

What happened

Shares of Emergent BioSolutions (EBS 2.54%) were falling 4% as of 11:07 a.m. EDT on Thursday after sinking as much as 7.6% earlier in the day.

The stock tumbled earlier this week after the company was forced to halt production at its Bayview facility in Baltimore, Maryland, while the U.S. Food and Drug Administration (FDA) conducted an inspection. This facility had been used to manufacture Johnson & Johnson's COVID-19 vaccine, although no doses had been yet distributed for use in the U.S.

The FDA issued a scathing report from this inspection on Wednesday. These problems led Cowen analyst Boris Peaker to lower his firm's price target for the healthcare stock to $67 per share from $86.

Long rows of COVID-19 vaccine vials

Image source: Getty Images.

So what

There's one silver lining with Peaker's lower price target: It's higher than Emergent's current share price. However, the company has a lot to overcome for investors' confidence to be restored.

First, Emergent BioSolutions must address the FDA's concerns about its Bayview facility. The company stated in a press release that it "is committed to working with the FDA and Johnson & Johnson to quickly resolve the issues identified." It added that the issues "are correctable and we will take swift action to remedy them."

That could be the easiest hurdle for Emergent BioSolutions to jump. The company might have a tougher time winning manufacturing contracts from other drugmakers with its highly publicized problems.

Now what

Investors will obviously want to closely monitor Emergent BioSolutions' actions in remediating the issues at its Bayview facility. It will be even more important to watch the company's quarterly updates over the next year to see if the quality problems at the facility impact the company's financial results.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$31.83 (2.54%) $0.79
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.